Axonics (NASDAQ:AXNX) quickly edged higher by 0.8% after a Nasdaq delisting notice for its planned sale to Boston Scientific ...

Meeting to be held on November 15 hosted by Oppenheimer. Published first on TheFly – the ultimate source for real-time, market-moving ...

Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy.

Shares of Boston Scientific Corp. rose 1.1% in premarket trades Wednesday after the medical products company reported better-than-expected profit and sales in its third-quarter results ...

As Boston Scientific’s pulsed field ablation business continues to grow, the medtech aims to nourish the program with the ...

On an adjusted basis, Boston Scientific reported earnings of 63 cents a share, above the FactSet consensus of 59 cents a share. Sales were $4.209 billion, up 19.4% from $3.527 billion in the prior ...

Boston Scientific expects to complete enrollment in the coming months in the study comparing pulsed field ablation to ...

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: ...

Marlborough-based Boston Scientific increased its estimated net sales growth for 2024. Meanwhile, Thermo Fisher slightly raised its full-year adjusted earnings per share guidance. Boston ...

Strong sales of a medical device to treat atrial fibrillation helped lift Boston Scientific’s top line last quarter, but an unexpected pause in an important clinical trial to expand the use of ...

That said, let's delve into the average estimates of some Boston Scientific metrics that Wall Street analysts commonly model and monitor. It is projected by analysts that the 'Net Sales ...